Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation

Hepatology

Volumn 54, Issue 3, 2011, Pages 868-878

  Sangro, Bruno ^a   Carpanese, Livio ^b   Cianni, Roberto ^c   Golfieri, Rita ^d   Gasparini, Daniele ^e   Ezziddin, Samer ^f   Paprottka, Philipp M ^g   Fiore, Francesco ^h   Van Buskirk, Mark ⁱ   Ignacio Bilbao, Jose ^a   Maria Ettorre, Giuseppe ^j   Salvatori, Rita ^c   Giampalma, Emanuela ^d   Geatti, Onelio ^e   Wilhelm, Kai ^f   Thorsten Hoffmann, Ralf ^g   Izzo, Francesco ^h   Iñarrairaegui, Mercedes ^a   Ludovico Maini, Carlo ^b   Urigo, Carlo ^c   Cappelli, Alberta ^k   Vit, Alessandro ^e   Ahmadzadehfar, Hojjat ^f   Franz Jakobs, Tobias ^g   Lastoria, Secondo ^h   more..

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SANTA MARIA GORETTI HOSPITAL   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSITY HOSPITAL BONN   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ Data Reduction LLC   (United States)

^j SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^k UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN; RADIOACTIVE MICROSPHERE; RESIN MICROSPHERE Y 90; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; DIGESTIVE SYSTEM ULCER; FATIGUE; FEMALE; FEVER; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OVERALL SURVIVAL; PNEUMONIA; PORTAL VEIN OBSTRUCTION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION HAZARD; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; YTTRIUM RADIOISOTOPES;

EID: 80052023374     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24451     Document Type: Article

References (31)

1. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160: 3227-3230.
2. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
3. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
4. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort. HEPATOLOGY 2005; 41: 707-716.
5. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006; 44: 723-731.
6. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54: 411-418.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. HEPATOLOGY 2011; 53: 1020-1022.
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. HEPATOLOGY 2003; 37: 429-442.
9. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Hepatobiliary guidelines. V.2.2010. last accessed June 8th, 2011.
10. Jelic S, Sotiropoulos GC, on behalf of the ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2010;(21 Suppl. 5): v59-v64.
11. 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004; 60: 1552-1563.
12. Sangro B, D'Avola D, Iñarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Exp Opin Pharmacother 2011; 12: 1057-1073.
13. 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 792-800.
14. Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127: S194-S205.
15. Ettorre GM, Santoro R, Puoti C, Sciuto R, Carpanese L, Antonini M, et al. Short-term follow-up of radioembolization with yttrium-90 microspheres before liver transplantation: new perspectives in advanced hepatocellular carcinoma. Transplantation 2010; 90: 930-931.
16. 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. HEPATOLOGY 2008; 47: 71-81.
17. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64.
18. 90Y resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21: 1205-1212.
19. Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005; 16: 205-213.
20. 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004; 10: S107-S110.
21. 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009; 74: 1494-1500.
22. Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112: 1538-1546.
23. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium. Int J Radiat Oncol Biol Phys 2007; 68: 13-23.
24. Coldwell D, Sangro B, Wasan H, Salem R, Kennedy A. General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol 2011; 34: 337-341.
25. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
26. 90Y Microspheres. New York, NY: Springer Verlag; 2008.
27. Hill T, Lewicki P. Statistics: methods and applications: a comprehensive reference for science, industry, and data mining. Tulsa, OK: StatSoft, Inc.; 2006.
28. Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol 2010; doi:10.1097/COC.0b013e3181df0a50.
29. Kulik LM, Atassi B, Van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94: 572-586.
30. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
31. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time to progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 497-507.